Effects of pirarubicin combined with cisplatin bladder perfusion chemotherapy on the expressions of VEGF and HER-2 in patients with early bladder cancer
Abstract：Objective To investigate the effects of pirarubicin combined with cisplatin bladder perfusion chemotherapy on the expressions of vascular endothelial growth factor (VEGF) and human epidermal growth factor receptor (HER-2) in patients with early bladder cancer.Methods Eighty patients with early bladder cancer who were treated in our hospital were divided into control group (n =40) and trial group (n =40) by means of lot method.The patients in both groups were treated by chemotherapy after surgery,the patients in control group were treated by routine chemotherapy with cisplatin,however,the patients in trial group,on the basis of control group,were treated by pirarubicin bladder perfusion chemotherapy.After treatment the changes of expression levels of VEGF and HER-2,life quality,clinical curative effects,relapse rate,survival rate,adverse reaction were observed and compared between two groups..Results After treatment,the expression levels of VEGF in trial group were significantly lower than those in control group [(52.30 ± 3.41) ng/L vs (56.844 ± 4.37) ng/L,P ＜ 0.05].Moreover the low expression rate and overexpression rate of HER-2 in trial group were superior to those in control group (P ＜ 0.05).The patient's life quality in trial group was superior to that in control group (P ＜ 0.05).The objective remission rate in trial group was 87.50％ (35/40),which was significantly higher than that [62.50％ (25/40)] in control group (P ＜ 0.05).The relapse rate and survival rate in trial group were superior to those in control group (P ＜ 0.05).Moreover there were no significant differnces in the incidence rates of adverse reaction between two groups (P ＞ 0.05).Conclusion The pirarubicin combined with cisplatin bladder perfusion chemotherapy can improve obviously the expression levels of VEGF,regulate the expression of HER-2 and improve the life quality of patients with early bladder cancer.
Keywords：pirarubicincisplatinbladder perfusionvascular endothelial growth factorhuman epidermal growth factor receptor 2early bladder cancer
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 840-843 )